Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

  • Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20. doi: 10.1128/AAC.00819-20.
Sangeun Jeon   #  1 ,  Meehyun Ko   #  1 ,  Jihye Lee  1 ,  Inhee Choi  2 ,  Soo Young Byun  3 ,  Soonju Park  3 ,  David Shum  3 ,  Seungtaek Kim  4
Affiliations
  • 1. Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
  • 2. Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.
  • 3. Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea.
  • 4. Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea [email protected].
  • # Contributed equally.
PMID: 32366720 DOI: 10.1128/AAC.00819-20
Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential Antiviral drug candidates against SARS-CoV-2 Infection. Some drug candidates showed very low 50% inhibitory concentrations (IC50s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

Keywords
COVID-19; FDA-approved drug; SARS-CoV-2.
Products